Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Matinas Biopharma Holdings, Inc. (OTC: MTNB).

Full DD Report for MTNB

You must become a subscriber to view this report.


Recent News from (OTC: MTNB)

Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors
BEDMINSTER, N.J., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform techn...
Source: GlobeNewswire
Date: September, 06 2018 08:01
Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
BEDMINSTER, N.J., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform tech...
Source: GlobeNewswire
Date: September, 05 2018 08:00
Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop
BEDMINSTER, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technol...
Source: GlobeNewswire
Date: August, 16 2018 08:00
Matinas Biopharma Holdings Q2 revenues up 125%
Matinas Biopharma Holdings ( MTNB ) Q2 results : Revenues: $0.09M (+125.0%). More news on: Matinas Biopharma Holdings, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: August, 10 2018 08:41
Matinas Biopharma Holdings reports Q2 results
Matinas Biopharma Holdings (NYSEMKT: MTNB ): Q2 EPS of -$0.04 More news on: Matinas Biopharma Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 10 2018 08:20
Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update
– Management intently focused on advancing proprietary and highly differentiated lipid nano-crystal platform delivery technology – – Multiple discussions with strategic partners remain ongoing – – ­Lead platform-validating asset, MAT2203, ...
Source: GlobeNewswire
Date: August, 10 2018 08:15
Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks
Stock Research Monitor: MGTA, MTNB, and MYOK LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration . WallStEquities.com revisits the Biotechnology space, which uses biological processes in the development or...
Source: ACCESSWIRE IA
Date: July, 25 2018 07:40
NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology
- Development program to focus on combination of antisense oligonucleotides with Matinas’ Proprietary LNC Delivery Technology - BEDMINSTER, N.J. and WASHINGTON, July 09, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceut...
Source: GlobeNewswire
Date: July, 09 2018 09:15
Matinas BioPharma Announces Closing of $8.0 Million Public Offering
BEDMINSTER, N.J., June 22, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced...
Source: GlobeNewswire
Date: June, 22 2018 08:30
Matinas BioPharma Announces Pricing of $8.0 Million Public Offering
BEDMINSTER, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced...
Source: GlobeNewswire
Date: June, 19 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.780.7640.78990.755206,107
2018-12-130.800.78090.80890.7519240,774
2018-12-120.780.790.80870.7575419,178
2018-12-110.750.76470.77040.73452,950
2018-12-100.780.750.8080.74277,866

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2017-03-01152,638252,34860.4871Short
2017-02-2882,355167,09049.2878Short
2017-02-2793,512219,31842.6376Short
2017-02-2450,36781,42461.8577Short
2017-02-23117,815245,10948.0664Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MTNB.


About Matinas Biopharma Holdings, Inc. (OTC: MTNB)

Logo for Matinas Biopharma Holdings, Inc. (OTC: MTNB)

Matinas BioPharma is a clinical stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life threatening infections. The Company s proprietary, disruptive technology utilizes lipid crystal nano particle cochleates to nano encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company s lead drug candidate is MAT , an orally administered, encochleated formulation of amphotericin B a broad spectrum fungicidal agent . The Company has an open Investigational New Drug IND application for MAT , which is an orally administered, encochleated formulation of amikacin a broad spectrum aminoglycoside antibiotic agent for acute bacterial infections, including non tuberculous mycobacterium NTM and multi drug resistant gram negative bacterial infections. For more information, please visit www.matinasbiopharma.com lt / td gt

 

 

 

Current Management

  • Roelof Rongen / CEO
  • Jerry Jabbour / President, General Counsel, EVP
  • Gary Gaglione / Interim CFO
  • Abdel Fawzy / EVP, Bus. Affairs
  • Douglas F. Kling / Senior VP
  • Raphael J. Mannino / CSO, CTO
  • Herbert Conrad / Chairman
  • Stefano Ferrari /
  • Roelof Rongen /
  • James Scibetta /
  • Adam Stern /

Current Share Structure

  • Market Cap: $97,217,746 - 03/09/2018
  • Authorized: 250,000,000 - 03/01/2018
  • Issue and Outstanding: 93,478,602 - 03/01/2018
  • Float: 31,187,778 - 01/20/2017

 


Recent Filings from (OTC: MTNB)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 26 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: September, 14 2017

 

 


Daily Technical Chart for (OTC: MTNB)

Daily Technical Chart for (OTC: MTNB)


Stay tuned for daily updates and more on (OTC: MTNB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MTNB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MTNB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MTNB and does not buy, sell, or trade any shares of MTNB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/